Pulmonary Embolism After Tirzepatide: Novel Safety Case Report
First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this GLP-1/GIP dual agonist with a potential thromboembolic signal.
Quick Facts
What This Study Found
First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this GLP-1/GIP dual agonist with a potential thromboembolic signal.
Key Numbers
Patient in her early 40s. D-dimer elevated at 1340 ng/mL. CT confirmed right main pulmonary artery PE. Onset 20 days after starting tirzepatide.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.
- Published In:
- BMJ case reports, 18(7) (2025)
- Authors:
- Alsararatee, Hasan H
- Database ID:
- RPEP-09905
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
First report of pulmonary embolism following tirzepatide use adds to pharmacovigilance data for this GLP-1/GIP dual agonist with a potential thromboembolic signal.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09905APA
Alsararatee, Hasan H. (2025). Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.. BMJ case reports, 18(7). https://doi.org/10.1136/bcr-2025-266561
MLA
Alsararatee, Hasan H. "Novel finding of pulmonary embolism following tirzepatide (Manjaro) use in a young adult without risk factors of venous thromboembolic events.." BMJ case reports, 2025. https://doi.org/10.1136/bcr-2025-266561
RethinkPeptides
RethinkPeptides Research Database. "Novel finding of pulmonary embolism following tirzepatide (M..." RPEP-09905. Retrieved from https://rethinkpeptides.com/research/alsararatee-2025-novel-finding-of-pulmonary
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.